Prevalence of non-A non-B hepatitis and anti-HCV antibodies in a Portuguese dialysis population.
Non-A Non-B hepatitis (NANBH) is nowadays one of the most common causes of hepatic dysfunction in dialysis patients. We reviewed the records of 231 HBsAg-negative patients in our unit and found 119 patients with biochemical criteria of NANBH (51.5%), 88 of them (68.9%) with circulating antibodies against HCV (chi 2 P less than 0.0001). Such high prevalence of NANBH was due to an outbreak of NANBH in the late 70s and early 80s. Time on haemodialysis (HD) was the major risk factor of NANBH in this population, and no other risk factors were identified. Prevalence of anti-HCV was similar to reports from non-uraemic populations. Anti-HCV seems to be a reliable test to confirm NANBH, but not better than using common biochemical criteria of NANBH to manage these patients in dialysis units.
Carrera
F
F
Centro Medico Nacional, Lisbon, Portugal.
Silva
J G
JG
Pires
C
C
Oliveira
C
C
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016174:Hepacivirus / Q000276:immunology*; D006508:Hepatitis Antibodies / Q000032:analysis*; D006526:Hepatitis C / Q000453:epidemiology*; D018937:Hepatitis C Antibodies; D006801:Humans; D008875:Middle Aged; D011174:Portugal / Q000453:epidemiology; D015995:Prevalence; D006435:Renal Dialysis / Q000009:adverse effects*
D006508:Hepatitis Antibodies; D018937:Hepatitis C Antibodies